

---

# 消化器内科学教室

---

## 2025 年度 英語原著論文

1. Hibi T, Kobayashi T, Tanaka M, Osaga S, Potts Bleakman AJ, Hunter Gible T, Nedeljkovic Protic M, Redondo I, Matsuo K, Hisamatsu T. Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn's Disease: Results from the Japanese CONFIDE Study. *Adv Ther.* 2025;42(4):1834-1859. doi: 10.1007/s12325-024-03078-3.
2. Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G. Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. *J Crohns Colitis.* 2025;19(4):jjae164. doi: 10.1093/ecco-jcc/jjae164.
3. Matsumoto T, Hisamatsu T, Esaki M, Omori T, Sakuraba H, Shinzaki S, Sugimoto K, Takenaka K, Naganuma M, Bamba S, Hisabe T, Hiraoka S, Fujiya M, Matsuura M, Yanai S, Watanabe K, Ogata H, Andoh A, Nakase H, Ohtsuka K, Hirai F, Fujishiro M, Igarashi Y, Tanaka S. Guidelines for endoscopic diagnosis and treatment of inflammatory bowel diseases. *Dig Endosc.* 2025;37(4):319-351. doi: 10.1111/den.15002.
4. Hotta N, Ohmiya N, Hiraga H, Nakaji K, Osawa S, Omori T, Mitsufuji S, Hosoe N, Nouda S, Kobayashi T, Nakamura M, Oka S, Nonogaki K, Baba Y, Mukai R, Matsumoto H, Ikebuchi Y, Shimada M, Togashi K, Katsuki S, Sasaki Y, Sawada R, Kawano S, Furuta T, Tajiri H, Tanaka S. Nationwide multicenter prospective study on the usefulness, safety, and acceptability of colon capsule endoscopy in Japan. *Gastrointest Endosc.* 2025;101(5):1051-1063.e7. doi: 10.1016/j.gie.2024.11.004.
5. Naganuma M, Shiga H, Shimoda M, Matsuura M, Takenaka K, Fujii T, Yamamoto S, Matsubayashi M, Kobayashi T, Aoyama N, Saito D, Yokoyama K, Moriya K, Tsuchiya K, Shibui S, Kawamoto A, Shimizu H, Okamoto R, Sakamoto K, Yaguchi K, Kunisaki R, Akiyama S, Hayashi R, Hasui K, Kanmura S, Bamba S, Mishima Y, Kakimoto K, Sugimoto S, Nakazawa A, Abe T, Ogata H, Hisamatsu T : First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study . *J Gastroenterol.* 2025 ; 60(4) : 430-441. doi: 10.1007/s00535-025-02216-0.
6. Koroku M, Omori T, Murasugi S, Ito A, Yonezawa M, Nakamura S, Tokushige K, Nakai Y. Investigation of the Clinical Remission Course in Ulcerative Colitis from Tofacitinib Induction to Tapering or Withdrawal in Japanese Patients: A Single-Center Retrospective Study. *Inflamm Intest Dis.* 2025;10(1):115-124. doi: 10.1159/000545704.
7. Hisamatsu T, Miyoshi J, Oguri N, Morikubo H, Saito D, Hayashi A, Omori T, Matsuura

- M : Inflammation-Associated Carcinogenesis in Inflammatory Bowel Disease: Clinical Features and Molecular Mechanisms. *Cells*. 2025 ; 14(8) : 567. doi: 10.3390/cells14080567.
8. Matsuoka K, Igarashi A, Sato N, Mizuno N, Ishii M, Iizuka M, Iwasaki K, Shoji A, Hisamatsu T : Clinical characteristics of patients with difficult-to-treat ulcerative colitis: a nested case-control study using a Japanese claims database. *Intest Res*. 2025. doi: 10.5217/ir.2024.00119.
  9. Takeuchi K, Nakase H, Hisamatsu T, Matsuoka K, Arai S, Yuasa H, Oe M, Ono R, Keating M, Gu G, Lazin K, McDonnell A, Fukuta K, Hibi T : Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study. *Intest Res*. 2025. doi: 10.5217/ir.2024.00213.
  10. Yamazaki H, Nagahori M, Hisamatsu T, Kobayashi T, Omori T, Limdi JK, McLaughlin JT, Wei SC, Fernandez J, Fukuhara S, Matsuoka K : Lifestyle restrictions are associated with impaired quality of life but not reduction in relapse in ulcerative colitis. *Intest Res*. 2025. doi: 10.5217/ir.2024.00199.
  11. Vermeire S, Nitcheu J, Gineste P, Flatres A, Santo J, Scherrer D, Peyrin-Biroulet L, Dulai PS, Danese S, Dubinsky M, Tilg H, Siegmund B, Hisamatsu T, Shan K, Rabbat C, Sands BE. Obefazimod in Patients with Moderate-to-Severely Active Ulcerative Colitis: Efficacy and Safety Analysis from the 96-week Open-label Maintenance Phase 2b study. *J Crohns Colitis*. 2025;19(5):jjaf074. doi: 10.1093/ecco-jcc/jjaf074.
  12. Nishinarita Y, Miyoshi J, Kuronuma S, Wada H, Oguri N, Hibi N, Takeuchi O, Akimoto Y, Lee STM, Matsuura M, Kobayashi T, Hibi T, Hisamatsu T. Characteristic gene expression profile of intestinal mucosa early in life promotes bacterial colonization leading to healthy development of the intestinal environment. *Sci Rep*. 2025;15(1):18437. doi: 10.1038/s41598-025-03661-w.
  13. Kobayashi T, Hisamatsu T, Motoya S, Matsuura M, Fujii T, Kunisaki R, Shibuya T, Takeuchi K, Hiraoka S, Yasuda H, Yokoyama K, Takatsu N, Maemoto A, Tahara T, Tominaga K, Shimada M, Kuno N, Cavaliere M, Ishiguro K, Fernandez JL, Hibi T. The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study. *Intest Res*. 2025. doi: 10.5217/ir.2024.00126.
  14. Akiyama S, Park SH, Baek JE, Kanai S, Takahara N, Kasuga R, Nakamoto N, Takagi Y, Shinzaki S, Weng MT, Wei SC, Fujisawa T, Isayama H, Harindranath S, Desai D, Liang J, Park D, Park SJ, Mizuno S, Mochida S, Hei-Tung Lai K, Yan Mak JW, Khoo XH, Hilmi I, Ishikawa N, Gu YB, Zhang H, Oh SJ, Sano Y, Honzawa Y, Cheng TF, Matsuoka K, Kim DH, Fujima T, Matsuura M, Kim KO, Jang BI, Yen HH, Jung SA, Suen TL, Ni YH, Naganuma M. Prevalence and Outcomes of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: A Multinational Study Across Asia. *Clin Gastroenterol Hepatol*. 2025:S1542-3565(25)01004-3. doi: 10.1016/j.cgh.2025.11.020.

15. Hisamatsu T, Kobayashi T, Motoya S, Fujii T, Kunisaki R, Shibuya T, Matsuura M, Hiraoka S, Takeuchi K, Yasuda H, Yokoyama K, Takatsu N, Maemoto A, Tahara T, Tominaga K, Shimada M, Kuno N, Fernandez JL, Hirose L, Ishiguro K, Cavaliere M, Hibi T. Real-World Effectiveness and Safety of Vedolizumab in Patients  $\geq 70$  Versus  $< 70$  Years With Ulcerative Colitis: Multicenter Retrospective Study. *J Gastroenterol Hepatol*. 2025;40(6):1435-1445. doi: 10.1111/jgh.16936.
16. Ogino Y, Sadashima K, Yoshida Y, Takedomi H, Tsuruoka N, Sakata Y, Takamori A, Hisamatsu T, Matsumoto T, Esaki M. Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn's disease. *J Gastroenterol*. 2025;60(6):705-714. doi: 10.1007/s00535-025-02235-x.
17. Chen B, Ye BD, Cao Q, Hirai F, Saruta M, Chen M, Pelak S, Shipitofsky N, Miao Y, Herr K, Wahking B, Zhuo J, Hisamatsu T. Guselkumab in East Asians With Moderate-to-Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies. *J Gastroenterol Hepatol*. 2025. doi: 10.1111/jgh.17036.
18. Omori T, Wada H, Mitsui T, Hayashida M, Hibi N, Saito D, Hisamatsu T. Capsule Endoscopy in Inflammatory Bowel Disease: Current Status and Issues in Clinical Practice. *DEN Open*. 2025;6(1):e70166. doi: 10.1002/deo2.70166.
19. Louis E, Schreiber S, Hisamatsu T, Hibi T, Jamoul C, Muller K, Taliadouros V, Oortwijn A, Peyrin-Biroulet L, Feagan BG. Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trial. *Dig Liver Dis*. 2025;57(7):1411-1418. doi: 10.1016/j.dld.2025.04.036.
20. Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gobble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. *Inflamm Bowel Dis*. 2025;31(7):1876-1890. doi: 10.1093/ibd/izae253.
21. Tokunaga K, Miyoshi S, Hojo F, Yonezawa H, Ida Y, Oka K, Takahashi M, Kamiya S, Miyoshi J, Hisamatsu T, Osaki T. Comparative study of gastric microbiota between patients with autoimmune gastritis and those with atrophic gastritis. *Sci Rep*. 2025;15(1):27658. doi: 10.1038/s41598-025-12211-3.
22. Regueiro M, Fischer M, Bossuyt P, Protic M, Traxler K, Yu G, Zang H, Vadhariya A, Hisamatsu T, Juillerat P, Armuzzi A, Gisbert JP, Walsh A. Impact of Mirikizumab Treatment on Fatigue in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study. *J Crohns Colitis*. 2025;19(7):jjaf100. doi: 10.1093/ecco-jcc/jjaf100.
23. Kudo T, Arai K, Iwama I, Hagiwara SI, Ishige T, Yokoyama K, Kakuta F, Jimbo K, Kondou H, Takaki Y, Kurasawa S, Fujikawa H, Koike Y, Hirai F, Ashizuka S, Watanabe K, Shimizu T, Hisamatsu T. Expert consensus on diagnostic guidelines for pediatric

inflammatory bowel disease in Japan. *J Gastroenterol.* 2025;60(9):1118-1144. doi: 10.1007/s00535-025-02271-7.

24. Wagatsuma K, Nojima M, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Takeuchi K, Tamura S, Kinjo F, Ueno N, Naganuma M, Watanabe K, Moroi R, Nishimata N, Motoya S, Kurahara K, Takahashi S, Maemoto A, Hiraga H, Saruta M, Tominaga K, Hisabe T, Tanaka H, Terai S, Inokuchi T, Takedomi H, Narimatsu K, Endo K, Nakamura M, Hisamatsu T, Nakase H; J-DESIRE Group. Post Hoc Analysis of Anxiety and Behavioral Changes in Japanese Patients With Inflammatory Bowel Disease due to the COVID-19 Pandemic: Relationship Between Municipal Population at the Place of Residence and Anxiety. *JGH Open.* 2025;9(7):e70209. doi: 10.1002/jgh3.70209.
25. Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panés J, Danese S, Hisamatsu T, Terry NA, Salese L, Van Rampelbergh R, Sahoo A, Vetter ML, Yee J, Han C, Frustaci ME, Wan KYY, Yang Z, Johanns J, Andrews JM, D'Haens GR, Sands BE; GALAXI 2 & 3 Study Group. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. *Lancet.* 2025:S0140-6736(25)00681-6. doi: 10.1016/S0140-6736(25)00681-6.
26. Kobayashi T, Hisamatsu T, Motoya S, Fujii T, Kunisaki R, Shibuya T, Matsuura M, Takeuchi K, Hiraoka S, Yasuda H, Yokoyama K, Takatsu N, Maemoto A, Tahara T, Tominaga K, Shimada M, Kuno N, Cavaliere M, Ishiguro K, Fernandez JL, Hibi T. Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study. *Intest Res.* 2025. doi: 10.5217/ir.2025.00047.
27. Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study. *Gastroenterology.* 2025 Aug;169(2):308-325. doi: 10.1053/j.gastro.2025.02.033.
28. Matsuoka K, Motoya S, Yamamoto T, Matsuura M, Fujii T, Shinzaki S, Mikami Y, Arai S, Oshima J, Endo Y, Yuasa H, Hoshi M, Sato K, Hisamatsu T. Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data. *J Gastroenterol.* 2025;60(8):979-989. doi: 10.1007/s00535-025-02249-5.
29. Ogihara R, Matsuura M, Ishida T, Morikubo H, Mitsui T, Saito D, Miyoshi J, Shibahara J, Sunami E, Hisamatsu T. A case of ulcerative colitis in a patient undergoing surgery due to exacerbation resulting in toxic megacolon after SARS-CoV-2 vaccination. *Clin J Gastroenterol.* 2025;18(4):557-562. doi: 10.1007/s12328-025-02136-9.
30. Kimizuka T, Yoshida A, Ueno F, Endo Y, Kato Y, Matsuoka K, Hisamatsu T, Hibi T.

Histological Predictors for Therapeutic Response to Integrin Inhibitors in Patients with Ulcerative Colitis. *Inflamm Intest Dis.* 2025;10(1):224-232. doi: 10.1159/000547013.

31. Oguri N, Kobayashi C, Ozawa Y, Kimura T, Nishinarita Y, Wada H, Nemoto N, Narita M, Tanigaki S, Hanawa T, Miyoshi J, Hisamatsu T : Vaginal *Lactobacillus crispatus* in early pregnancy associates with favorable gestational outcomes in a Japanese maternal-neonatal microbiome cohort. *Nat Commun.* 2025;16(1):8032. doi: 10.1038/s41467-025-63466-3.
32. Hibi N, Kuronuma S, Takeuchi O, Tablante MC, Miyoshi J, Matsuura M, Hisamatsu T, Kobayashi T. Mechanism of IL-10 production via IL-1R in gut macrophages. *Biochem Biophys Res Commun.* 2025;786:152702. doi: 10.1016/j.bbrc.2025.152702.
33. Nakase H, Fujii T, Hisamatsu T, Suzuki Y, Watanabe M, Takahashi S, Ooi M, Takeuchi K, Kimura T, Furuya K, Aoyama N, Hasatani K, Horiki N, Kanke K, Tokito S, Sai S, Uchikawa Y, Goto S, Fujimoto G, Zhang C, Petersen A, Hibi T. Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North Study. *Gastro Hep Adv.* 2025;5(1):100812. doi: 10.1016/j.gastha.2025.100812.
34. Takenaka K, Hisamatsu T, Kobayashi T, Yamamoto H, Ohmiya N, Hayashi R, Matsuoka K, Saruta M, Andoh A, Fukata N, Watanabe K, Imaeda H, Hirai F, Matsumoto T, Hirakawa A, Yano T, Matsuura M, Okamoto R, Ohtsuka K, Watanabe M. Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn's Disease; a prospective multicenter study. *Clin Gastroenterol Hepatol.* 2025;23(11):1991-2000. doi: 10.1016/j.cgh.2024.10.030.
35. Panaccione R, Ferrante M, Dotan I, Panés J, Hisamatsu T, Bossuyt P, Danese S, Song A, Kalabic J, Joshi N, Zambrano J, Zhang Y, Duan WR, Kligys K, Dubinsky MC, Lindsay JO, Vermeire S, Siegmund B, Irving PM, D'Haens G. Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment. *Clin Gastroenterol Hepatol.* 2025;23(11):2012-2022.e6. doi: 10.1016/j.cgh.2024.12.023.
36. Fujisawa T, Toki M, Saito K, Hasegawa Y, Iwasaki E, Saito M, Kitamura K, Tonozuka R, Itoi T, Ito K, Kaneko K, Takahara N, Hisamatsu T, Isayama H. Comparison of the Usefulness of Covered and Uncovered Laser-cut Metal Stents. *DEN Open.* 2025;6(1):e70208. doi: 10.1002/deo2.70208.
37. Nakamura T, Wagatsuma K, Hayashi Y, Morikubo H, Saito D, Idogawa M, Nojima M, Miyoshi J, Matsuura M, Hisamatsu T, Nakase H. Impact of Mediterranean Fever Gene Mutations on Clinical Characteristics in Patients With Inflammatory Bowel Disease. *Gastro Hep Adv.* 2025;5(2):100836. doi: 10.1016/j.gastha.2025.100836.
38. Saito D, Matsuura M, Morikubo H, Hibi N, Komatsu H, Oguri N, Fujima T, Wada H, Ogihara R, Mitsui T, Hayashida M, Miyoshi J, Omori T, Hisamatsu T. Mayo Endoscopic Subscore at Week 24 Is a Predictor of Future Loss of Response to Vedolizumab in

Patients with Ulcerative Colitis in Clinical Remission. *Inflamm Intest Dis*. 2025;10(1):387-396. doi: 10.1159/000549404.

39. Matsuoka K, Yamamoto T, Matsuura M, Fujii T, Arai S, Endo Y, Sato K, Yuasa H, Mizuno Y, Kobayashi Y, Hisamatsu T. Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a post hoc analysis of safety and effectiveness in older ( $\geq 65$  years) and younger ( $< 65$  years) patients. *Intest Res*. 2025. doi: 10.5217/ir.2025.00058.
40. Herr K, Hisamatsu T. Authors' Reply to: Iqbal J, Ahmad A, and Iltaf A. "Letter to the Editor: Genetic and Pharmacokinetic Considerations in Guselkumab Treatment for Ulcerative Colitis in East Asian Patients". *J Gastroenterol Hepatol*. 2025. doi: 10.1111/jgh.70142.
41. Matsuoka K, Motoya S, Shinzaki S, Mikami Y, Adachi C, Arai S, Endo Y, Sato K, Yuasa H, Mizuno Y, Hisamatsu T. Post-marketing Surveillance of Tofacitinib in Patients With Ulcerative Colitis in Japan: A Post Hoc Analysis of Safety and Effectiveness by Prior Biologic Status. *Crohns Colitis* 360. 2025;7(4):otaf065. doi: 10.1093/crocol/otaf065.
42. Hisamatsu T, Kaise T, Nagakura C, Kamiya M, Wei SC. Efficacy and safety of filgotinib in the treatment of ulcerative colitis with a focus on rapid and sustained efficacy: a narrative review. *Intest Res*. 2025. doi: 10.5217/ir.2025.00155.
43. Sato T, Nagashima F, Okano N, Nishioka M, Hayashi M, Saito Y, Hisamatsu T, Hironaka S. Two cases of metastatic colorectal cancer in which epidermal growth factor receptor gene amplification benefited from panitumumab monotherapy. *Int Cancer Conf J*. 2025;15(1):114-120. doi: 10.1007/s13691-025-00826-2.
44. Matsuura M, Yoon A, Miyoshi J, Hisamatsu T. Escalation to biologics after corticosteroids in patients with newly diagnosed Crohn's disease in Japan: a claims analysis from 2010 to 2021. *Intest Res*. 2025. doi: 10.5217/ir.2025.00059.
45. Ohno A, Miyoshi J, Kusuhara M, Jinbo Y, Kaji R, Shirakawa T, Watanabe M, Tsubata S, Sumi R, Matsuura M, Iga K, Okabe M, Hisamatsu T. Image-enhanced endoscopy improves visibility of endoscopic images in individuals with color vision deficiency. *Endosc Int Open*. 2025;13:a27142766. doi: 10.1055/a-2714-2766.
46. Tsutsui A, Murakami Y, Nishiwaki Y, Asakura K, Ohfuji S, Fukushima W, Matsuoka K, Hisamatsu T. Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023. *J Gastroenterol*. 2025;60(12):1513-1522. doi: 10.1007/s00535-025-02295-z.
47. Matsuoka K, Hirai F, Watanabe K, Hokari R, Kobayashi T, Saruta M, Nakase H, Suzuki T, Yamazaki G, Hibi T, Watanabe M, Hisamatsu T. Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study). *J Gastroenterol*. 2025 Dec;60(12):1523-1534. doi: 10.1007/s00535-025-02299-9.

48. Kim HJ, Motoya S, Suzuki Y, Ohnishi Y, Marano CW, Imai Y, Wahking B, Zhuo J, Kawamura S, Hisamatsu T. Efficacy and Safety of Ustekinumab in Asian Patients with Moderately to Severely Active Ulcerative Colitis: A Subpopulation Analysis of UNIFI Long-Term Extension through 4 Years. *Inflamm Intest Dis.* 2025;11(1):65-79. doi: 10.1159/000549914.
49. Fukui S, Kishimoto M, Matsuura M, Sakamoto A, Ono K, Kobayashi S, Kawashima S, Ikegaya N, Kawakami T, Mitsui T, Saito D, Hayashida M, Miyoshi J, Komagata Y, Hisamatsu T. Prevalence, characteristics, and screening of spondyloarthritis in Japanese patients with early inflammatory bowel diseases: a prospective multidisciplinary study. *J Gastroenterol.* 2026;61(1):46-58. doi: 10.1007/s00535-025-02301-4.
50. Hisamatsu T, Miyoshi J, and Minoru M. Recent Advances in Molecular Targeted Therapy for Inflammatory Bowel Disease (Review) *Intern Med.* 2026;65(2):196-202. doi: 10.2169/internalmedicine.5491-25.
51. Toya Y, Shiotani A, Ono S, Saito Y, Sugimoto M, Naito Y, Nomura S, Handa O, Hisamatsu T, Fujishiro M, Matsuda T, Morita Y, Yahagi N, Chan FKL, Ang TL, Abdullah M, Tablante MC, Prachayakul V, Li B, Jung HY, Matsumoto T. Questionnaire survey on the current status of advanced therapy for inflammatory bowel disease in Asia. *Digestion.* 2026;107(1):103-113. doi: 10.1159/000549339.
52. Fukui T, Naganuma M, Kirino Y, Kunisaki R, Mikami Y, Ueno N, Umeno J, Bamba S, Ooi M, Hosomi S, Matsumoto T, Matsuoka K, Watanabe C, Nagahori M, Uchino M, Watanabe K, Hirai F, Matsuura M, Tanaka Y, Takeno M, Hisamatsu T. A Multicenter Observational Study for the Establishment of Novel Severity Criteria Including Endoscopic Evaluation for Intestinal Behçet's Disease. *Dig Endosc.* 2026;38(1):e70041. doi: 10.1111/den.70041.
53. Yanai S, Hisamatsu T, Matsumoto T. High Incidence of Metachronous Lesions After Endoscopic Removal in Patients With Ulcerative Colitis: Results of a Long-Term Follow-Up in Multicenter Registry Study. *Dig Endosc.* 2026;38(1):e70087. doi: 10.1111/den.70087.
54. Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L; ASTRO Study Group. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. *Lancet Gastroenterol Hepatol.* 2026:S2468-1253(25)00322-X. doi: 10.1016/S2468-1253(25)00322-X.
55. Schreiber S, Danese S, Colombel JF, Hisamatsu T, Irving PM, Park H, Kim DH, Lee YN, Hanauer SB. Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis. *Adv Ther.* 2026. doi: 10.1007/s12325-025-03447-6.

56. Morikubo H, Matsuura M, Komatsu H, Fujima T, Ogihara R, Oguri N, Mitsui T, Saito D, Hayashida M, Miyoshi J, Hisamatsu T. Clinical Significance of Endoscopic Improvement at 6 Months in Patients With Ulcerative Colitis Treated With Ustekinumab: A Retrospective Real-world Analysis. *DEN Open*. 2026;6(1):e70278. doi: 10.1002/deo2.70278.
57. Ishihara S, Tanaka S, Uraoka T, Saito Y, Takamaru H, Nakase H, Naganuma M, Hisamatsu T, Fujii T, Matsuura M, Matsumoto T, Watanabe K, Ikeuchi H, Uchino M, Okita Y, Okabayashi K, Koganei K, Sugita A, Takahashi K, Hata K, Higashi D, Futami K, Matsuda K, Mizushima T, Watadani Y, Kawachi H, Shimoda M, Sugai T, Yoshida M, Yamaguchi N, Itabashi M, Anzai H, Kishikawa J, Komatsu K, Shinagawa T, Tsushima T, Noguchi T, Okada S, Sugihara K, Ajioka Y. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia (English Version). *J Anus Rectum Colon*. 2026;10(1):135-168. doi: 10.23922/jarc.2025-071. eCollection 2026.
58. Liu W, Guo H, Kim TO, Takeuchi K, Hisamatsu T, Fable J, Olurinde M, Wahking B, Herr K, Zhuo J, Cao Q. Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the Phase 3 GRAVITI study. *Intest Res*. 2026. doi: 10.5217/ir.2025.00107.
59. Sands BE, Barnes EL, D'Haens G, Hisamatsu T, Regueiro M, Kelly CR, Laharie D, Hozak RR, Yu G, Gandhi R A, Lopes MU, Durand F, Protic M, Moses RE, Vermeire S. Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial. *Clin Gastroenterol Hepatol*. 2026:S1542-3565(26)00155-2. doi: 10.1016/j.cgh.2026.01.049.
60. Morikubo H, Miyoshi J, Hayashi A, Komatsu H, Yonezawa H, Matsuura M, Shibahara J, Hisamatsu T. Transabdominal intestinal ultrasound versus transmural histopathological findings in severe ulcerative colitis requiring colectomy. *Crohns Colitis* 360. 2026;8(1):otag017. doi: 10.1093/crocol/otag017.
61. Panaccione R, Melmed GY, Drobne D, Kaur M, Danese S, Hisamatsu T, Kalabic J, Chen S, Cheng L, Duan WR, Shah S, Louis E. Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment. *Clin Gastroenterol Hepatol*. 2026;24(5):1424-1433. doi: 10.1016/j.cgh.2025.09.007.
62. Kaji R, Ohno A, Miyoshi J, Sumi R, Tsubata S, Shirakawa T, Watanabe M, Miyamoto N, Kusahara M, Kurata M, Kataoka K, Okada AA, Matsuura M, Hisamatsu T. A case of pseudoxanthoma elasticum treated with endoscopic clip hemostasis for upper gastrointestinal bleeding from a Dieulafoy lesion. *Intern Med*. 2026. doi: 10.2169/internalmedicine.6566-25.
63. Ono K, Ohata K, Ide D, Ohno A, Muramoto T, Tsuji Y, Chiba H, Kato H. Potential for remote hands-on training system for colorectal endoscopic submucosal dissection. *VideoGIE*. 2025;10(8):428-433. doi: 10.1016/j.vgie.2025.03.037.

64. Shao X, Toyoshima N, Haga T, Kusuhara M, Kanemitsu Y, Shen J, Saito Y. First case of hemorrhoidal carcinoma in a fistulotomy scar: successful per-anal endoscopic myectomy despite severe fibrosis. *Endoscopy*. 2025;57(S 01):E1286-E1287. doi: 10.1055/a-2721-9065.
65. Kusuhara M, Sekiguchi M, Toyoshima N, Takamaru H, Yamada M, Kobayashi N, Hashimoto T, Hisamatsu T, Saito Y. Outcomes of subsequent endoscopic resection for rectal neuroendocrine tumors with positive/indeterminate vertical margins. *iGIE*. Published online October 14, 2025. doi: 10.1016/j.igie.2025.10.002.
66. Makiguchi M, Abe S, Fujimoto A, Kawagoe R, Uozumi T, Kusuhara M, Mizuguchi Y, Toyoshima N, Nonaka S, Suzuki H, Yoshinaga S, Kitabayashi I, Daiko H, Saito Y, Yahagi N. Color differences of intraprocedural bleeding between white light and red dichromatic imaging during endoscopic submucosal dissection: a post hoc analysis of a multicenter, open-label, randomized controlled trial (with videos). *Surg Endosc*. 2025;39(7):4402-4410. doi: 10.1007/s00464-025-11809-y.

## 2024 年度 英語原著論文

67. Tanaka H, Oka S, Shiotani A, Sugimoto M, Suzuki H, Naito Y, Handa O, Hisamatsu T, Fukudo S, Fujishiro M, Motoya S, Yahagi N, Yamaguchi S, Chan FKL, Lee SY, Li B, Ang TL, Abdullah M, Tablante MC, Prachayakul V, Tanaka S: International Gastrointestinal Consensus Symposium Study Group. Current Status of Diagnosis and Treatment of Colorectal Cancer in Asian Countries: A Questionnaire Survey. *Digestion*. 2024;105(1):62-68. doi: 10.1159/000531706.
68. Morikubo H, Tojima R, Maeda T, Matsuoka K, Matsuura M, Miyoshi J, Tamura S, Hisamatsu T: Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis. *Sci Rep*. 2024 Feb 22;14(1):4386. doi: 10.1038/s41598-024-55126-1.
69. Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group: Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. *Lancet Gastroenterol Hepatol*. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7.
70. Khalaf K, Seleq S, Bourke MJ, Alkandari A, Bapaye A, Bechara R, Calo NC, Fedorov ED, Hassan C, Kalauz M, Kandel GP, Matsuda T, May GR, Mönkemüller K, Mosko JD, Ohno A, Pavic T, Pellisé M, Raos Z, Repici A, Rex DK, Saxena P, Schauer C, Sethi A, Sharma P, Shaukat A, Siddiqui UD, Singh R, Smith LA, Tanabe M, Teshima CW, von Renteln D, Gimpaya N, Pawlak KM, Angeli Fujiyoshi MR, Fujiyoshi Y, Lamba M, Li S, Malipatil SB, Grover SC: Establishment of standards for the referral of large nonpedunculated colorectal polyps: an international expert consensus using a modified Delphi process. *Gastrointest Endosc*. 2024 Sep;100(3):510-516.e6. doi: 10.1016/j.gie.2024.02.001.

71. Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gible T, Abreu MT, Lee S, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Arora V, Panaccione R, Dignass A: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. *Inflamm Bowel Dis.* 2024 Dec 5;30(12):2245-2258. doi: 10.1093/ibd/izae024. Erratum in: *Inflamm Bowel Dis.* 2024 Jun 3;30(6):1044-1045. doi: 10.1093/ibd/izae096.
72. Komatsu H, Morikubo H, Kimura Y, Moue C, Yonezawa H, Matsuura M, Miyoshi J, Hisamatsu T: A combination of bowel wall thickness and submucosa index is useful for estimating endoscopic improvement in ulcerative colitis: external validation of the Kyorin Ultrasound Criterion. *J Gastroenterol.* 2024 Mar;59(3):209-215. doi: 10.1007/s00535-024-02077-z.
73. Naganuma M, Nakamura N, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, Saito D, Kobayashi T, Nanki K, Narimatsu K, Shiga H, Esaki M, Yoshioka S, Kato S, Saruta M, Tanaka S, Yasutomi E, Yokoyama K, Moriya K, Tsuzuki Y, Ooi M, Fujiya M, Nakazawa A, Takagi T, Omori T, Tahara T, Hisamatsu T: Japanese UC Study Group. Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria. *J Gastroenterol.* 2024 Apr;59(4):302-314. doi: 10.1007/s00535-024-02079-x.
74. Horanai C, Hashimoto H, Hisamatsu T, Ikeuchi H, Watanabe K, Nanjo S, Nezu R, Itabashi M, Hokari R, Higashi D, Matsuura M, Ogino T, Takahashi K, Andoh A, Shinozaki M, Sugita A: Association Between Sense of Coherence, Disease-Specific Symptoms, and Health-Related Quality of Life Among Japanese Patients with Ulcerative Colitis: A Cross-Sectional Study. *Digestion.* 2024;105(4):257-265. doi: 10.1159/000538618.
75. Kimura Y, Miyoshi J, Morikubo H, Komatsu H, Moue C, Yonezawa H, Matsuura M, Hisamatsu T: Early sonographic improvement predicts clinical remission and mucosal healing with molecular-targeted drugs in ulcerative colitis. *Gastro Hep Advances* 2024 Apr 23;3(6):703-710. doi: 10.1016/j.gastha.2024.04.007.
76. Nemoto N, Inami T, Onozawa S, Kohno T, Nagahama K, Soejima K, Hisamatsu T: A case report of limitation of transcatheter hepatic arterial embolization for hereditary hemorrhagic telangiectasia type 2 with pulmonary arterial hypertension. *Int J Surg Case Rep.* 2024 Apr 19;119:109634. doi: 10.1016/j.ijscr.2024.109634.
77. Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, Zhang H, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Peyrin-Biroulet L, Sands BE, Marano C: Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. *Am J Gastroenterol.* 2024 May 1;119(5):910-921. doi: 10.14309/ajg.0000000000002621.
78. Shibayama T, Hayashi A, Toki M, Kitahama K, Ho YJ, Kato K, Yamada T, Kawamoto S, Kambayashi K, Ochiai K, Gondo K, Okano N, Melchor JP, Iacobuzio-Donahue CA,

- Sakamoto Y, Hisamatsu T, Shibahara J: Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma. *Sci Rep.* 2024 Jul 6;14(1):15598. doi: 10.1038/s41598-024-65900-w.
79. Ohno A, Miyamoto N, Kaji R, Shirakawa T, Watanabe M, Sumi R, Jinbo Y, Kusuhara M, Miyoshi J, Hisamatsu T: The influence of color vision deficiency on vessel visibility during colorectal endoscopic submucosal dissection and the potential advantage of red dichromatic imaging to achieve color vision barrier-free. *DEN Open.* 2024 Jul 19;5(1):e410. doi: 10.1002/deo2.410.
  80. Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, Parra RS, Ford S, Remple VP, Lacerda AP, Anyanwu SI, Mallick M, Garrison A, Regueiro M: Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy. *Clin Gastroenterol Hepatol.* 2024 Aug;22(8):1668-1677. doi: 10.1016/j.cgh.2024.02.027.
  81. Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group: Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. *JAMA.* 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414.
  82. Oguri N, Miyoshi J, Nishinarita Y, Wada H, Nemoto N, Hibi N, Kawamura N, Miyoshi S, Lee STM, Matsuura M, Osaki T, Hisamatsu T: Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model. *NPJ Biofilms Microbiomes.* 2024 Sep 16;10(1):81. doi: 10.1038/s41522-024-00564-y.
  83. Takeuchi K, Hisamatsu T, Nakase H, Matsuoka K, Keating M, Yuasa H, Oe M, Arai S, Mazur R, Hibi T: Efficacy and safety of etrasimod in patients with ulcerative colitis in Japan: data from the phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN trials. *Digestion.* 2024 Sep 24;1-9. doi: 10.1159/000541383.
  84. Khalaf K, Seleg S, Bourke MJ, Alkandari A, Bapaye A, Bechara R, Calo NC, Fedorov ED, Hassan C, Kalauz M, Kandel GP, Matsuda T, May GR, Mönkemüller K, Mosko JD, Ohno A, Pavic T, Pellisé M, Raos Z, Repici A, Rex DK, Saxena P, Schauer C, Sethi A, Sharma P, Shaukat A, Siddiqui UD, Singh R, Smith LA, Tanabe M, Teshima CW, von Renteln D, Gimpaya N, Pawlak KM, Angeli Fujiyoshi MR, Fujiyoshi Y, Lamba M, Li S, Malipatil SB, Grover SC. Establishment of standards for the referral of large nonpedunculated colorectal polyps: an international expert consensus using a modified Delphi process. *Gastrointest Endosc.* 2024 Sep;100(3):510-516.e6. doi: 10.1016/j.gie.2024.02.001.
  85. Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gobble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A: Three-Year Efficacy and Safety of

Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. *Inflamm Bowel Dis*. 2024 Oct 25;izae253. doi: 10.1093/ibd/izae253.

86. Schreiber S, Feagan BG, Louis E, Hisamatsu T, Hibi T, Dron L, Jamoul C, Patel H, Harris K, Taliadouros V, Oortwijn A, Peyrin-Biroulet L: Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study. *United European Gastroenterol J*. 2024 Nov;12(9):1243-1255. doi: 10.1002/ueg2.12686.
87. Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G: Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. *J Crohns Colitis*. 2024 Nov 1;jjae164. doi: 10.1093/ecco-jcc/jjae164.
88. Hibi T, Hirohata S, Hisamatsu T, Kikuchi H, Takeno M, Sato N, Mizuno N, Tashiro M, Susuta Y, Ishigatsubo Y: Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet's Disease: A Post-Marketing Surveillance. *Adv Ther*. 2024 Dec;41(12):4476-4497. doi: 10.1007/s12325-024-02993-9.
89. Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gobble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. *Inflamm Bowel Dis*. 2024 Dec 5;30(12):2245-2258. doi: 10.1093/ibd/izae024.
90. Nakase H, Wagatsuma K, Kobayashi T, Matsumoto T, Esaki M, Watanabe K, Kunisaki R, Takeda T, Arai K, Ibuka T, Ishikawa D, Matsuno Y, Sakuraba H, Ueno N, Yokoyama K, Saruta M, Hokari R, Yokoyama J, Tamano S, Nojima M, Hisamatsu T: MEFV-IBDU Group. Involvement of Mediterranean fever gene mutations in colchicine-responsive enterocolitis: a retrospective cohort study. *EBioMedicine*. 2024 Dec;110:105454. doi: 10.1016/j.ebiom.2024.105454.
91. Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE: VIVID Study Group. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. *Lancet*. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8.
92. Takenaka K, Hisamatsu T, Kobayashi T, Yamamoto H, Ohmiya N, Hayashi R, Matsuoka K, Saruta M, Andoh A, Fukata N, Watanabe K, Imaeda H, Hirai F, Matsumoto T, Hirakawa A, Yano T, Matsuura M, Okamoto R, Ohtsuka K, Watanabe

- M: Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn's Disease; a prospective multicenter study. *Clin Gastroenterol Hepatol*. 2024 Dec 16:S1542-3565(24)01084-X. doi: 10.1016/j.cgh.2024.10.030.
93. Naganuma M, Takeno M, Çelik AF, Moots R, Pinton P, Hisamatsu T: Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives. *Biomedicines*. 2025 Jan 20;13(1):247. doi: 10.3390/biomedicines13010247.
  94. Okabe M, Yamamoto S, Shiokawa M, Hisamatsu T, Yamazaki H, Nakanishi R, Hamada K, Kitamoto H, Kuwada T, Uza N, Sakatani A, Fujii T, Ohno M, Matsuura M, Shibuya T, Ohmiya N, Ooi M, Hoshi N, Moriya K, Tsuchiya K, Yamaguchi Y, Kunisaki R, Takahara M, Takagi T, Takehara T, Hirai F, Kakimoto K, Esaki M, Nakase H, Kinjo F, Torisu T, Kanmura S, Narimatsu K, Matsuoka K, Hiraga H, Yokoyama K, Honzawa Y, Naganuma M, Saruta M, Kodama Y, Chiba T, Seno H: Anti-integrin  $\alpha v \beta 6$  antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study. *J Gastroenterol*. 2025 Jan;60(1):86-95. doi: 10.1007/s00535-024-02176-x.
  95. Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A: QUASAR Study Group. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. *Lancet*. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5.
  96. Kobayashi T, Hisamatsu T, Motoya S, Fujii T, Kunisaki R, Shibuya T, Matsuura M, Takeuchi K, Hiraoka S, Yasuda H, Yokoyama K, Takatsu N, Maemoto A, Tahara T, Tominaga K, Shimada M, Kuno N, Fernandez JL, Ishiguro K, Cavaliere M, Deguchi H, Hibi T: Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study. *Intest Res*. 2025 Jan 16. doi: 10.5217/ir.2024.00063.
  97. Komatsu H, Morikubo H, Kimura Y, Moue C, Yonezawa H, Matsuura M, Miyoshi J, Hisamatsu T: Determination of optimal cutoff value of ulcerative colitis intestinal ultrasound index to estimate endoscopic improvement in ulcerative colitis. *J Gastroenterol*. 2025 Feb;60(2):166-173. doi: 10.1007/s00535-024-02172-1.
  98. Miyoshi J, Hisamatsu T: Effect of maternal exposure to antibiotics during pregnancy on the neonatal intestinal microbiome and health. *Clin J Gastroenterol*. 2025 Feb;18(1):1-10. doi: 10.1007/s12328-024-02088-6.
  99. Panaccione R, Ferrante M, Dotan I, Panés J, Hisamatsu T, Bossuyt P, Danese S, Song A, Kalabic J, Joshi N, Zambrano J, Zhang Y, Duan WR, Kligys K, Dubinsky MC, Lindsay JO, Vermeire S, Siegmund B, Irving PM, D'Haens G: Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment. *Clin Gastroenterol Hepatol*. 2025 Feb 3:S1542-3565(25)00082-5. doi: 10.1016/j.cgh.2024.12.023.

100. Miyoshi J, Yoon A, Matsuura M, Hisamatsu T. Real-world use of biologics during the first year of treatment for newly diagnosed Crohn's disease in Japan: a claims analysis from 2010 to 2021. *Intest Res.* 2025 Jan 23. doi: 10.5217/ir.2024.00082.
101. Tsuzuki Y, Shiotani A, Miyaguchi K, Ono S, Saito Y, Sugimoto M, Naito Y, Nomura S, Handa O, Hisamatsu T, Fujishiro M, Matsuda T, Morita Y, Yahagi N, Chan FKL, Ang TL, Abdullah M, Tablante MC, Prachayakul V, Li B, Jung HY, Matsumoto H, Shiomi R, Imaeda H: Questionnaire Survey on the Diagnosis and Treatments of Eosinophilic Gastrointestinal Diseases (EGID) in Asia. *Digestion.* 2025 Feb 13:1-14. doi: 10.1159/000544725.
102. Hibi T, Kobayashi T, Tanaka M, Osaga S, Potts Bleakman AJ, Hunter Gible T, Nedeljkovic Protic M, Redondo I, Matsuo K, Hisamatsu T: Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn's Disease: Results from the Japanese CONFIDE Study. *Adv Ther.* 2025 Feb 28. doi: 10.1007/s12325-024-03078-3.
103. Hisamatsu T, Naganuma M, Pinton P, Takeno M: Behçet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan. *J Gastroenterol.* 2025 Mar;60(3):294-305. doi: 10.1007/s00535-024-02191-y.
104. Matsumoto T, Hisamatsu T, Esaki M, Omori T, Sakuraba H, Shinzaki S, Sugimoto K, Takenaka K, Naganuma M, Bamba S, Hisabe T, Hiraoka S, Fujiya M, Matsuura M, Yanai S, Watanabe K, Ogata H, Andoh A, Nakase H, Ohtsuka K, Hirai F, Fujishiro M, Igarashi Y, Tanaka S: Guidelines for endoscopic diagnosis and treatment of inflammatory bowel diseases. *Dig Endosc.* 2025 Mar 3. doi: 10.1111/den.15002.
105. Ogino Y, Sadashima K, Yoshida Y, Takedomi H, Tsuruoka N, Sakata Y, Takamori A, Hisamatsu T, Matsumoto T, Esaki M: Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn's disease. *J Gastroenterol.* 2025 Mar 7. doi: 10.1007/s00535-025-02235-x.
106. Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study. *Gastroenterology.* 2025 Mar 18:S0016-5085(25)00522-0. doi: 10.1053/j.gastro.2025.02.033.